A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer

Eli Lilly and Company130 enrolled

Overview

The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine in patients with pancreatic cancer.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

130

Conditions

Pancreatic Cancer

Interventions

GemcitabineDRUG

LY293111DRUG

placeboDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adenocarcinoma of the pancreas that is locally advanced or metastatic and not amenable to resection with curative intent * Tumor that can be measured by x-ray or scan * Adequate organ function Exclusion Criteria: * Inability to swallow capsules * Documented brain metastases * Prior chemotherapy or biological therapy for this disease

Locations (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5pm Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.

Lakeland, Florida, United States

Outcomes

Primary Outcomes

6-month survival

Secondary Outcomes

Toxicity

tumor response

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.